October 8,Florida-based Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on redefining vision possibilities, announced the completion of a $78 million Series D financing round to support the commercial launch of Qlosi™ 0.4% (Pilocarpine Hydrochloride Ophthalmic Solution) — a novel corrective eye drop for presbyopia in adults that received FDA approval for market release last October. The Series D round included $68 million in equity, co-led by Arboretum Ventures and Johnson & Johnson Innovation, with participation from Catalio Capital Management, Freepoint Capital Group (FCG), existing investor Visionary Ventures, and Bluestem Capital.SBI (Japan) Innovation Fund、Sequoia CapitalAlong with Maverick Ventures and other individual participants. While conducting equity financing, Orasis has secured $15 million in structured capital from Catalio Capital Management, of which $10 million will be drawn at closing.
Elad Kedar, CEO of Orasis Pharmaceuticals, said:"We are proud to partner with leading, high-quality investors who share our commitment to redefining the possibilities of vision for older adults seeking freedom from reading glasses. This substantial funding will enable us to successfully launch Qlosi, offering the ophthalmic care community a nearsightedness solution that balances efficacy and tolerability using the lowest approved effective concentration."Pilocarpine。”Paul McCreadie, Managing Partner of Arboretum Ventures, stated:"We are delighted to co-lead this financing round and join a consortium of experienced investors, whose collective support further validates Qlosi's market potential. We are confident in the Orasis team's ability to successfully launch Qlosi and positively impact patients' myopia."Follow the official account below to see the world!
